CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to improve treatment for acute myeloid leukemia by identifying specific vulnerabilities linked to mutations in the nucleophosmin 1 protein. By discovering small molecules that selectively target these mutated cells, the project seeks to develop more effective therapies with fewer side effects.
Less than 25% of patients diagnosed with acute myeloid leukemia (AML) survive longer than 5 years.
Current treatment regimen are based on non-specifically acting cytotoxic drugs that cause severe side effects.
More effective and more specific, targeted therapies are thus needed.
Progress, however, has long been hampered by a lack of understanding of the molecular vulnerabilities of the disease.
We here propose to identify and study synthetic lethal interactions with mutations in nucleophosmin 1…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
